Recent genome-wide association studies (GWAS) have identified numerous schizophrenia (SZ) associated loci. As is common across disorders, many of the SZ associated variants are located outside protein-coding regions and are hypothesized to differentially affect the transcription of nearby genes. To systematically identify which variants affect potential regulatory activity, we assayed 1,049 variants in high Linkage Disequilibrium (LD) within 64 reported SZ-associated loci and an additional 30 SNPs from 9 loci associated with Alzheimer's disease (AD) using a massively parallel reporter assay (MPRA). Each variant was assayed on the center of a 95bp synthetic oligonucleotide. The resulting library was transfected 3 independent times into K562 chronic myelogenous leukemia lymphoblasts and another 6 times into SK-SY5Y human neuroblastoma cells. We identified 148 SNPs with significant allelic differences in their effect on expression of the reporter gene in the K562 cells and 53 in the SK-SY5Y cells with an average of 2.6 such SNPs per locus and a median of 1. The overlap between cell lines was modest with 9 SNPs having significant allelic differences in both lines, 8 of these 9 in the same direction. We do not observe a direction preference (increased or decreased enhancer activity) for risk vs. non risk alleles. We find that large LD blocks have a greater density of functional SNPs supporting instances of combinatorial SNP effects that may lead to selection at the haplotype level. Our results help determine driver GWAS variant(s), guide the functional follow up of disease associated loci and enhance our understanding of the genomic dynamics of gene regulation.
Introduction
Over the last decade collaborative genome wide association studies (GWAS) have identified thousands of DNA variants that show robust associations with an array of complex phenotypes [1] . For example, over 100 independent loci have been identified contributing to the risk for schizophrenia (SZ) [2, 3] and based on recent reports from the SZ working group of the psychiatric genomics consortium (PGC, World Congress of Psychiatric Genetics 2017, Orlando, FL) over twice that number of loci will soon be published. In Alzheimer's disease (AD) a large meta-analysis in 2013 [4] reported 19 risk loci, of which 11 were novel.
Identifying reliable associations of genetic variants with disease has been a significant first step towards understanding the causes of neuropsychiatric disorders such as SZ and AD. Understanding their functional consequences and linking them to specific affected genes and biological processes is the next step to unlock their translational potential.
Across disorders GWAS have taught us some important lessons that help with this goal.
For one, variants are most often located in non-coding sequences, and 40% of the time their haplotype blocks do not include coding exons [5] [6] [7] . Further, they concentrate in regions of regulatory DNA marked by deoxyribonuclease I (DNase I) hypersensitive sites (DHSs) [8] , and Quantitative Trait Loci (eQTL) studies suggest that they are often regulatory [5, 9, 10] . It must be noted that such studies likely underestimate how often disease variants are regulatory since variation in the time, place or circumstances under which a regulatory sequence is activated can lead to false negatives both for regulatory DNA marks and eQTLs.
Typically each GWAS locus contains multiple variants in high linkage disequilibrium (LD), all of which show strong evidence of association. This restricts efforts to identify the one or few variants that drive the association signal at a given locus and to evaluate their functional consequences. For each locus that is associated with disease risk, there must be at least one strongly correlated functional variant explaining the observed association, while it is possible that in some loci there are more than one functional variants in LD with each other along with other "passenger" variants. Such loci might contain specific haplotypes under selective pressure because of their distinct functional profiles, as recently reported for Mendelian disease mutations [11] . Episomal reporter assays have been commonly used to assess the potential of DNA sequences to drive transcription and to identify functional variants among the many in LD. In these assays, a plasmid is constructed carrying the candidate enhancer sequence inserted next to a minimal promoter driving the expression of a reporter gene. The plasmid is transfected into cells without genome integration and the expression of the reporter gene is measured and compared across different sequences. More recently, to meet the needs of genome level analysis, these types of assays have been redesigned to achieve higher throughput.
Examples of such high throughput assays include massively parallel reporter assays (MPRA) [12] that examine thousands of candidate sequences in parallel and selftranscribing active regulatory region sequencing (STARR-seq) which screen entire genomes for enhancers based on their activity [13] .
Because of our interest in SZ and the large number of reported robust associations, we chose to survey the regulatory landscape of GWAS loci for this complex disorder using a custom MPRA assay, and interrogate the differential regulatory activity of the disease-associated sequences and the differences between risk and non-risk alleles. In our list of variants of interest and because of available space on the synthesis array, we included a few of the variants reported to be associated with AD, another interest of our laboratory.
As each of these robust associations is bound to be driven by variants of some biological importance, identifying variants that alter enhancer activity in-vitro can be a means to screen for the subset of variants among the many in LD that are of functional significance. 
Results

MPRA design
As described in detail in the methods our final MPRA design included oligonucleotides 
MPRA quality checks
Barcode representation Table 1 . Barcode and element representation across cell lines. Sample size for rows 1 to 4 is 10,106 barcodes. Sample size for rows 5 and 6 is 2,383 elements. The ranges in rows 1 and 2 indicate a range over the 3 or 6 samples represented in a column.
Of the initial 11,935 designed barcodes, 1,829 were never present in DNA or RNA. We consider the remaining pool of 10,106 barcodes (corresponding to 2,383 elements of the 
Correlation of count and activity measures between samples
To summarize count information for each MPRA element, we sum counts over barcodes to obtain one count per element per sample. These aggregated counts are used to compute activity measures
This estimator is expected to have lower bias than an estimator that uses the mean of barcode-specific activity measures [14] . show between-sample correlations ranging from 0.519 to 0.607 ( Figure 3 ). In the second batch, between-sample correlations were low, ranging from 0.104 to 0.251. Generally, correlations between samples within a single cell line are higher than correlations between samples in different cell lines. Figure 4 ). The correlations for the second batch of SH-SY5Y cells were low and we considered removing them from analysis, we found however that including it did increase our power for detecting activity differences. We note that the lower correlations between activity measures in SH-SY5Y are driven by an increased abundance of inactive elements, whose activity measures are simply noise. We do see higher correlation between samples for the active elements.
All SNPs and their p-values for differential activity in either cell line are listed in supplementary table 1. The same file includes a tab listing SNPs that only reached significance with the inclusion of batch 2 . Based on previous experience of our laboratory, we believe that the lower performance of the SH-SY5Y cell line is largely due to the nature of these cells. In our experience, these cells are more difficult to transfect and show lower efficiencies compared to K562. 
Activity of positive and negative control sequences
In the K562 cell line, the EEF1A1 promoter sequences (positive control) showed significantly higher activity than the negative control sequences (95% CI for difference in log-ratio activity measures: 0.50-1.12). We should note that the negative control was chosen for the absence of evidence of being an enhancer, but we have no evidence that definitely exclude such function.
In the SH-SY5Y cell line, the EEF1A1 promoter sequences when examined all together did not show significantly higher activity measures than the negative control sequences in either of the two batches (Batch 1 95% CI for difference in log-ratio activity measures: -0.25-0.33. Batch 2 95% CI for difference in log-ratio activity measures: -0.31-0.21). We noticed however that not all the EEF1A1 promoter sequences which were tiled in overlapping segments show activity. This is illustrated in Figure 5 where When we select sub-sets of EEF1A1 oligos at different activity levels in the K562 cell line and compare to the negative control oligos, we see that above a certain threshold these subsets of positive controls also show significantly higher activity than the negative controls in both batches of the neuronal line ( Figure 6 ). Not surprisingly, batch 1 shows significant increases in positive control activity over a wider range of thresholds than batch 2. show significantly higher activity than the negative controls. In batch 2, only the most highly active positive control oligos show significantly higher activity than negative controls.
Evaluation of variants that show differential enhancer activity
Location of SNPs with differential enhancer activity
We successfully assayed 1,079 SNPs and found 144 SZ and 4 AD SNPs that show differential enhancer activity between alleles (significant allelic skew) in the K562 cell line and 50 and 3 in the SH-SY5Y cell line (FDR < 0.05). These SNPs, which we call significant SNPs for the purposes of this paper, are located on several different chromosomes ( Figure 7 ). Nine SNPs showed allelic differences in both K562 and SH- 
There is no preferred direction of effect on enhancer/repressor activity for risk versus non-risk alleles
If a SNP exerts its influence in SZ or AD risk by affecting an enhancer for a nearby gene, is it more likely to decrease or increase enhancer activity? To explore this question, we overlaid our MPRA results with GWAS information on effect directions. Because of the larger number of SNPs and to avoid exploring different diseases together we did the analysis only for SZ SNPs.
Of the 144 significant SZ SNPs in K562, 81 (56%, 95% binomial CI: 47%-64%) are SNPs for which the risk allele from GWAS shows lower MPRA enhancer activity than the non-risk allele. Of the 50 significant SZ SNPs in SH-SY5Y 25 (50%, 95% binomial CI: 35%-65%) are SNPs for which the risk allele shows lower MPRA enhancer activity.
Overall, these results suggest that there is no specific direction of effect on expression characterizing disease risk variants. It must be noted however that this analysis examines the effect of each individual SNP on the disease-associated haplotype in isolation. It is likely that selection has favored LD of alleles with opposing effects, balancing each other towards a favorable combined effect. It is also likely that there are interactions between such regulatory sequences that are not captured in our experiment.
MPRA activity levels show concordance with chromatin accessibility measures
We find that MPRA activity levels in the two cell lines show good overlap with cell line- 
Identification of disrupted features contributing to differential activity
We searched for transcription factor (TF) binding motifs overlapping SNP positions and compared binding scores between alleles to assess potential disruptions in TF binding.
We used the union of the JASPAR2016 and ENCODE databases for a total of 2450 TF motifs. The main match metric that we use is the relative score, which is the ratio of the observed position weight matrix (PWM) score at a given position divided by the maximum possible score for the PWM. Relative scores fall between 0 and 1. Due to the large number of motifs examined, most SNPs in our MPRA assay showed "convincing" binding (high relative score) for at least one TF motif. In fact, all MPRA SNPs have at least one TF motif match with a relative score of at least 0.963 (Figure 9 ). Given that a PWM relative score gives a measure of how strongly a particular TF might bind to a region, we found it reasonable to ask if a higher score was associated with higher enhancer activity as measured by our MPRA. For each match between a TF motif and an MPRA oligo, we obtained a PWM relative score for each allelic version of the oligo. For each MPRA oligo, we could also compute the mean activity level for each allele from MPRA data. We determined whether the PWM relative scores for the different alleles were positively or negatively correlated with the mean activity levels for the different alleles. We did not observe a correlation of PWM with MPRA activity levels in either the K562 or the SH-SY5Y cell line. This is probably expected given the noise in examining such a wide variety of motifs across so many sequences.
Support for combinatorial SNP effects leading to large LD blocks
Ours [15] and others' work [16] suggests that within large LD blocks there are often multiple regulatory variants that presumably combine their effects in regulating their target gene. In such genomic regions selective pressure is likely to favor specific arrangements of alleles to optimally combine positive and negative regulators. By doing so selection may drive the formation of larger haplotypes containing more functional SNPs along with some passenger SNPs in LD. In such regions the fraction of functional SNPs !!"#$%&"'( !!"#$%&"'(!!!""#$%#&" would be greater than in genomic regions where only one SNP is functional and all others are passengers. Our data that include a mix of smaller and larger LD groups provides an opportunity to test this hypothesis. We did so on our K562 cell line data, as it had the most positive results. We did not include positives from SH-SY5Y to avoid confounding from differences in regulation between cell lines. We first tested whether blocks that include more SNPs have a higher fraction of positives !"#$"%"&'$( !"" !"#$ !" !" in our assay than smaller blocks. The upper bar graph in Figure 10 shows the fraction of significant SNPs at different LD block sizes. We observed that blocks of fewer than 20 SNPs showed a smaller fraction of significant SNPs, a difference that was highly significant (Chi-square p = 7.5e-4, top of Figure 10 ) even if we were to test all 8 possible cut offs (corrected p=0.006). There was also a reverse trend from small to very small blocks. This reversal may be because every block is expected to contain at least one functional SNP, but for very small blocks the fraction !"#$"%"&'$( !"" !"#$ !" !" will also have a small denominator. If we remove the expected 1 significant SNP for every block in each size bin and graph the excess significant SNPs for every bin we see a much more pronounced difference between larger and smaller blocks (blue bars at bottom graph in Figure 10 ). We stress, however that this correction introduces a bias and this graph is only meant to illustrate the point, not to assess statistical significance of this effect.
Discussion
We report the results of an MPRA for SNPs associated with SZ and AD on two different cell lines, K562 and SH-SY5Y. The purpose of this work is to add to the data available to us and other investigators in the effort to sort among the multiple SNPs showing statistical associations with disease and identify those likely to have a functional consequence. We report a total of 192 SNPs among the total of 1079 tested (18%) that show statistically significant allelic differences (FDR = 0.05) in driving reporter gene expression. While we recognize the many caveats inherent to such experiments as discussed below, we consider these variant sequences strong candidates for underlying the observed disease associations and an important resource for SZ and AD research.
There are a number of observations that support the validity of our results. The differences between our positive and negative controls along with the concordance of direction of signals that emerged as significant in both cell types are all consistent with true signals. The significant and cell type specific overlap with open chromatin marks is also an expected feature of true signals. Whether a higher overlap should be expected between the two cell lines is less clear. One might also argue that it would be expected to observe more eQTLs among the loci harboring significant SNPs. The numbers of eQTLs we observe are already high at ~70% of tested loci. Whether we would see a enrichment in the loci showing allelic differences in our MPRA depends on many factors including the differences between the cell lines we used and the DLPFC bulk tissue that was used to identify eQTLs.
Despite the evidence for the validity of the data there remain important caveats to keep into consideration. First, the results from the SH-SY5Y cells were significantly weaker than those of the K562 cells. We had expected that SH-SY5Y being a neuroblastoma cell line would be more informative for studying brain disorders than the K562 chronic myelogenous leukemia cell line. Unfortunately, our experience has been that SH-SY5Y cells are much less efficient for transfection both in these and in other experiments. This explains both the lower oligo representation and the lower yield of positive results. We should note that, in fact, K562 might be a very relevant cell type for neuropsychiatric phenotypes. For one, K562 is enriched for genes expressed in immunity-related tissues reported by the PGC for the SZ GWAS signals. We have also observed that the overlap of chromatin marks and SZ SNPs is higher for K562 cells than SK-N-SH-RA that SH-SY5Y are derived from (5.4% of all SZ SNPs we assayed overlap K562 DGF hotspots compared to 5.1% overlapping SK-N-SH-RA DGF hotspots). Further, the overlapping significant SNPs between the two cell types, while highly consistent in direction, are relatively few. While it would be encouraging to observe more overlaping SNPs, this is not necessarily of concern. The activity of an episomally-introduced sequence can be influenced by numerous factors, including the combinations of transcription factors present in each cell type and the likely necessity of combinatorial effects with other enhancers that may be absent in the 95 bp DNA fragments that we test here. Finally, it must be noted that all the caveats affecting classic reporter assays, an artificial expression system, also apply here. The risk of false negatives is high, while false positives can also not be ruled out in the case that a tested variant resides in closed chromatin in the disease- 
Conclusion
In summary, we have screened 1,079 disease associated variants and found that 192 show significant allelic differences in driving reporter gene expression. These were located on 54 of 73 tested disease loci or almost three quarters. Many of the 54 loci contained more than one regulatory variant in LD and we observed a relative increase of signal density in larger LD blocks, which might indicate complex regulation and selection of haplotypes that combine specific regulatory alleles as previously suggested by us and others [15, 16] .
The results of our large screen of disease associated variation will be a significant spring board to facilitate future research on the genetics of these disorders and the complex role of gene regulation.
Materials and methods
Selection of variants
Variants were selected from two large GWAS, one for schizophrenia [3] and one for
Alzheimer's disease [4] . The schizophrenia PGC2 data was downloaded from https://www.med.unc.edu/pgc/ which provides data on the association between schizophrenia and 9,444,231 imputed SNPs across the genome. We first determined the size of the groups of SNPs that were in LD with each other and therefore represented the same association signal. To maximize the number of independent loci investigated in our assay while comprehensively examining each tested locus, we followed specific selection rules. First, we identified the lead SNPs at each locus and identified all SNPs in the same locus with p-values up to 15 times larger. To maximize efficiency, we excluded loci where more than 45 SNPs fit this criterion (the only exception was a block on chromosome 2 with 92 SNPs). This resulted in 1,198 SNPs in 64 schizophrenia loci moving forward to oligonucleotide design. Next we added SNPs from the AD GWAS [4] . Here we first used the lead SNPs reported by Lambert to identify all SNPs in strong LD (r 2 > 0.9) using the bioinformatics tool SNAP [17] . The largest LD groups were then removed resulting in the addition of 30 SNPs across 9 AD GWAS loci to our assay, for a total of 1,228 SNPs selected to be included in the MPRA. All successfully assayed SNPs and the results of our assay are in supplementary Table 1 .
MPRA design and methods
Oligonucleotides of 150 bp including 95 bp centered on each SNP and 45 flanking based for amplification and cloning purposes (see below) were synthesized for each sequence of interest, as described in [18] and [19] . Target sequences were flanked with a multiple cloning site, a unique tag and primers for PCR amplification (Figure 1 The library we received from the BROAD institute was amplified, cloned and transfected as described [18, 19] with slight modifications. The experimental design is summarized in Figure 1 . First, using the primer sequences built into the synthetic oligos the library was amplified through a low-cycle (25 cycles) PCR reaction in 7 separate wells to preserve oligo representation and minimize PCR bias ( Figure 1A ). The 7 PCR products were gelpurified and pooled together for subsequent steps. The primers used for PCR introduced two distinct SfiI sites as described [19] . These sites were used for the subsequent directional cloning (1st cloning site in Figure 1A ) into the pMPRA1 plasmid (Addgene ID# 49349, Figure 1B) . The plasmids were used to transform E.Coli by electroporation.
The synthesized oligos contained a second directional cloning site (restriction enzymes KpnII, XbaI) which was used in the next step to insert a CMV minimal promoter driving GFP between the putative regulatory sequence and the corresponding tag sequence within the synthesized oligonucleotide (2nd cloning site, Figure 1C ). After these two rounds of cloning -E.Coli transformation, we used the resulting plasmid library to perform three independent transfections of K562 chronic myelogenous leukemia cells and six independent transfections in SH-SY5Y human neuroblastoma cells in two batches by lipofectamine3000 (Thermofisher Scientific cat. no L3000008). We then extracted DNA and RNA and performed 50 bp non-paired end sequencing reading from the 3'end, through the unique tag and into the GFP transcript on an ILLUMINA MiSeq DNA Sequencer (Illumina, Inc. San Diego, CA). For each triplicate transfection we acquired 10
-27 million reads of DNA and RNA.
Differential analysis
Before statistical analysis, we normalize both the RNA and DNA counts using total count normalization. That is, we scale the counts in each sample so that all samples have the same library size. For differential analysis of MPRA activity levels between alleles, we use the mpralm method [14] . This approach uses linear models to directly model activity measures and uses a combination of observation-level weighting and empirical Bayes methods to improve estimation of element-specific variances. In our study, comparisons of activity measures between alleles are paired in the sense that each biological replicate measures the activity of all (2 or more) alleles of a SNP. The assaying of all alleles simultaneously in a given sample leads to correlation between their measurement, and for this reason, we use the mixed model approach of mpralm for making comparisons.
Our data for the SH-SY5Y cell line come from two separate batches, so before differential analysis we use the ComBat method [20] to correct the log-ratio activity measures. This method estimates location and scale parameters of batch effects at the element level and moderates these estimates using an empirical Bayes technique that pools information on these estimates across all elements. With these parameter estimates, batch-corrected outcome measures can be computed. From here, we proceed as detailed above with differential analysis.
Transcription factor binding analysis
To search for transcription factor (TF) motifs that can be affected by the SNPs in our study, we used the TFBSTools package available on Bioconductor [21] . We used the union of the JASPAR2016 and ENCODE TF databases for a total of 2450 motifs. We only considered matches in which the motif overlapped the SNP position within the oligo and in which the position weight matrix (PWM) score was at least 70% of the maximum score possible for the PWM (i.e. a relative score of at least 70%) for at least one allele of a SNP.
Comparisons with open chromatin measures
To assess whether MPRA active elements where overlapping with cell line-specific digital genomic footprinting (DGF) tracks we downloaded from UCSC the following files: hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeUwDgf, file names wgEncodeUwDgfK562Hotspots.broadPeak.gz and wgEncodeUwDgfSknshraHotspots.broadPeak.gz. These correspond to data from K562 cells and retinoic acid treated SK-N-SH cells. SH-SY5Y are a sub-clone of SK-N-SH which is the closest cell line for which we could access DGF data.
